Background: Antipsychotic use for behavioural and psychological symptoms of dementia (BPSD) is controversial. Guidelines advise to reduce antipsychotics given the adverse effects and limited efficacy, to limit dose and treatment duration as well as to undertake discontinuation. Methods: A pilot study with 40 hospitalised geriatric cognitively impaired patients, in which the effects of abrupt antipsychotic discontinuation were investigated, using neuropsychiatric inventory (NPI) scores before and one month after discontinuation. Withdrawal symptoms were monitored thrice a day with a checklist during five consecutive days. Results: Participants (n ¼ 40) had a mean age of 84 years (range 67-95) and 53% were male. The total mean baseline NPI score was 21 (SD 12) with predominantly behavioural rather than psychological disturbances. After abrupt discontinuation, mild withdrawal symptoms were observed in 72% of the patients, with frequencies of symptoms peaking on day 2 (53%) and day 3 (48%). After one month, 31 patients (85%) were still off antipsychotics and improved on the majority of NPI domains, with a total mean NPI score decreasing from 18 (SD 13) to 12 (SD 8, p ¼ 0.003). In the relapse group, there was no deterioration associated with the abrupt discontinuation and subsequent resumption of therapy with a total mean NPI score decreasing from 31 (SD 12) at baseline to 27 (SD 8) at one-month follow-up (p ¼ 0.345). Conclusion: Abrupt antipsychotic discontinuation appears to be feasible in older individuals with BPSD. Systematically performed discontinuation efforts in clinical practice are needed to differentiate between patients where antipsychotics have no added value and patients where the benefits outweigh the risks.
Introduction
The appropriateness of antipsychotic therapy for behavioural and psychological symptoms of dementia (BPSD) in older persons has been debated extensively and is a controversial topic. In fact, BPSD will affect about 50-80% of people with dementia, in varying degrees during their course of illness (Lyketsos et al., 2002) . Evidence suggests modest, limited efficacy for some specific symptoms within the BPSD spectrum (Ballard & Waite, 2006) , but the potential of benefit is overshadowed by potential harm. In the UK, Banerjee (2009) concluded that there is minimal evidence for improvement in global behavioural disturbance by using antipsychotics (effect size 0.1-0.2), but a significant increase of absolute mortality risk. Kleijer et al. (2009) reported that only 18% of patients with dementia starting with antipsychotics improved on their behaviour, while 49% deteriorated. Stroke, falls and consecutive fractures, cognitive decline as well as deep vein thrombosis (Banerjee, 2009; Liperoti et al., 2009 ) have been reported as adverse effects of antipsychotics in older persons, and even in shortterm trials (Schneider, Dagerman, & Insel, 2005) . While trials had a time span of less than 12 weeks, antipsychotics are far more longer used in clinical practice (Azermai, Elseviers, Petrovic, van Bortel, & Stichele, 2011) . Therefore, serious concerns with regard to the long-term effects exist. For all these reasons, guidelines (NICE, 2007; SIGN, 2006) advise to minimise antipsychotic use in older persons with dementia; to initiate antipsychotics only in severe distress after a risk-benefit analysis, and to limit treatment duration with attempts of discontinuation. Few studies investigated antipsychotic discontinuation (Ballard et al., 2004 (Ballard et al., , 2009 Bridges-Parlet, Knopman, & Steffes, 1997; Cohen-Mansfield et al., 1999; Ruths, Straand, Nygaard, & Aarsland, 2008; van Reekum et al., 2002) and often with methodological limitations.
Moreover, these studies have not explored the possibility of discontinuation in a hospital setting, and the immediate effects of abrupt cessation with attention to withdrawal phenomena. Mostly, they have *Corresponding author. Email: majda.azermai@ugent.be focused on nursing home residents with Alzheimer's dementia; including only participants with mild symptoms; assessing different outcome measures on different times; including limited antipsychotic classes or not differentiating between antipsychotic or benzodiazepine withdrawal; and mostly implementing gradual discontinuation by tapering the dose.
Our pilot study was an observational uncontrolled cohort study aiming to explore the feasibility of abrupt antipsychotic discontinuation in hospitalised, cognitively impaired geriatric patients, and the effects with regard to withdrawal phenomena, re-occurrence of neuropsychiatric symptoms and relapse to antipsychotics over time.
Methods

Institutions and patients
We conducted an observational study with hospitalised geriatric patients in a convenience sample of hospitals. The feasibility of abrupt antipsychotic discontinuation was explored in long-term users, who should be considered for discontinuation in accordance with best care practice. Patients were found eligible for study participation if:
. they had a confirmed clinical diagnosis of dementia or cognitive impairment assessed by the Mini-Mental State Examination (MMSE 25);
. they used antipsychotics explicitly for behavioural and psychological symptoms; and . the antipsychotic use was initiated before hospitalisation (at home or in the nursing home) or (in the case of a long length of hospital stay) antipsychotics were used for at least one month during hospitalisation; and treating physician and researchers agreed on behavioural stability of the patient (Figure 1 ).
For patients on high-dose antipsychotics, an old age psychiatrist was consulted regarding the risk of severe withdrawal symptoms associated with the abrupt discontinuation. Patients using antipsychotics for neuropsychiatric conditions with the exception of dementia were excluded, as well as delirium, and terminally ill patients.
Procedure
Prior to the study, the medical and nursing staff of the participating geriatric wards was informed with regard to the study. Information was given about the rationale for conducting this study, explaining that undertaking antipsychotic discontinuation efforts should be embedded in usual care practice. Physicians and nurses were asked to contact the principle investigator when patients on antipsychotics were admitted to the hospital.
Further screening of the patients was done by the researcher, based on medical records, contact with general practitioner (GP) and family members. Informed consent was collected from the participants, and/or their proxy. When the patient was found eligible, the treating physician was asked to give the order to cease the antipsychotic treatment. A baseline neuropsychiatric inventory (NPI) was assessed by interviewing a responsible nurse, GP or family member having close contact with the patient in the last 4 weeks before abrupt antipsychotic discontinuation was started. Study participants were meticulously observed by the physician and the nursing staff during five consecutive days after the abrupt discontinuation. The observers used a checklist (see further) deliberately designed for this study (based on literature) to detect possible withdrawal symptoms. This checklist was filled out thrice a day by the early, late and night nursing shift. One month after the date of discontinuation, the NPI was re-assessed by interviewing the responsible nurse or treating physician. When the patient was discharged from the hospital, the follow-up was performed by telephone interview of the main caregiver, head nurse (nursing home) or GP.
Data collection
We collected administrative data (e.g. reason of hospital admission, length of hospital stay) and clinical data of all study participants. Administrative data also included activities of daily living (ADL; Katz & Akpom, 1976) which ranks the six functions of bathing, dressing, toileting, transferring, continence and feeding. Clinical data included type of dementia, MMSE and clinical problems (retrieved from the medical records). The main outcome measure for this study was the NPI, which covers 12 domains of behavioural and neurovegetative symptoms: delusions or paranoia, visual and auditory hallucinations, agitation or aggression, depressed mood or dysphoria, anxiety, elation or euphoria, apathy or indifference, disinhibition (impulsive), irritability or lability (decreased coping), motor disturbance (pacing, compulsive behaviours), night-time behaviour problems (e.g. sleep disturbance), appetite or eating problems (e.g. weight loss). The antipsychotic withdrawal checklist was developed based on the literature (Dilsaver & Alessi, 1988; Gardos, Cole, & Tarsy, 1978) and included four psychological symptoms (anxiety, restlessness, insomnia, hallucinations) and 10 physical symptoms. Malignant neuroleptic syndrome is a serious but rare event described not only when antipsychotic doses are augmented but also when antipsychotics are withdrawn (Amore & Zazzeri, 1995) . This event was also included on the list and highlighted as a dangerous adverse event. The checklist also allowed for nurses' observations of other symptoms during the consecutive five days follow-up.
Data handling
The six domains of ADL were summed into a physical dependency score: the higher the score, the more physically dependent (total score ranging from minimum 6 to maximum 24). The NPI that covers 12 neuropsychiatric domains, differentiates in frequency (absent, or a range from 1 to 4) and severity of symptoms (range 1-3). We calculated each item by multiplying frequency and severity: the higher the score, the more severe the neuropsychiatric item (ranging from minimum 1 to maximum 12 per item). We also calculated a total NPI score that ranged from minimum 12 to a theoretical maximum of 144. The items of the withdrawal checklist (psychological and physical symptoms) were calculated into a total score, indicating the frequency of withdrawal symptoms per shift and per day.
Statistical analysis
The data were analysed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Differences, comparison of means between groups, and associations were analysed through cross-tabulation, variance analysis and correlations. The level of significance was set at p 5 0.05. For data analysis, the study population was divided into two subgroups: a successfully discontinued group and a relapse group. Successful discontinuation was defined as still being antipsychotic-free, one month after the date of abrupt discontinuation. We explored baseline differences among the two groups as well as mean changes in the 12 NPI domains before and one month after antipsychotic discontinuation. Also, we performed an analysis on NPI clusters to detect differences in larger defined areas being mood (i.e. euphoria, depression, apathy and appetite), restlessness (i.e. aberrant motor activity, night-time behaviour problems, anxiety and disinhibition), psychosis (i.e. delusions and hallucinations) and agitation (i.e. agitation/aggression, irritability). The success or relapse over time (in days) was examined using Kaplan-Meier survival analysis where an event was defined as the re-initiation of antipsychotics.
Ethical considerations
This study was approved by the Ethics Committee of the Ghent University Hospital (approval no. 2010/662) and of Hospital Network Antwerp (approval no. 3751). Abrupt discontinuation was approved by the treating physician in all cases. A written informed consent was provided by the patient and/or by proxy.
Results
Description of the institutions
We included three institutions, a university hospital, a general hospital and a specialised psychogeriatric clinic. This clinic is specialised in dementia diagnostics and offers treatment strategies for patients with varying degrees of cognitive impairment. Study participants were recruited from the geriatric ward of the university hospital (30 beds) and the general hospital (48 beds) as well as from the specialised psychogeriatric clinic (60 beds). The admission profile varies between the institutions with acute admissions and short hospital stay mainly in the university hospital, while in the general hospital there is a mix of acute admissions and longer hospitalisations pending institutionalisation. The psychogeriatric clinic partially acts as a transition place pending institutionalisation, resulting in a longer hospital stay.
Description of the population
We enrolled 40 patients in the study (March-November 2011) . Study participants had a mean age of 84 years (range 67-95) and were in 53% male. Patients had high physical dependency scores with a mean ADL of 16 (range 6-24) and had severe cognitive impairment (mean MMSE 16, range 4-25). In 34 patients, there was a clinically confirmed diagnosis of dementia. In the remaining six patients, there was no established diagnosis of dementia, but cognitive impairment existed (based on the MMSE) with behavioural disturbances for which antipsychotics were prescribed. Study participants suffered in 55% from Alzheimer's dementia, in from 15% vascular dementia, in from 15% dementia associated with Parkinson's disease and in 15% there was no medical diagnosis of dementia (cognitive impaired). The main reason for admission was general deterioration (Table 1) . A small variance was found between the institutions with a physical illness as the main reason for admission in the university hospital, and cognitive diagnostic work-up as the main reason for admission in the specialised clinic.
The mean length of hospital stay varied per institution with a mean of 14 days in the university hospital, 18 days in the general hospital and 168 days in the memory clinic. Study participants had several underlying diseases, with cardiovascular problems in 83% of patients (Table 1) .
Description of antipsychotic use
All patients received antipsychotics at stable doses. In eight patients, there was duplicate use. Atypical antipsychotics accounted for 73% of the total use. Median (range) daily doses of the main prescribed antipsychotics were: risperidone 1 mg (0.25-2), quetiapine 82 mg (50-100), olanzapine 5 mg (5-10), haloperidol 2 mg (1-5). In six patients, a geriatric psychiatrist was consulted regarding the abrupt discontinuation because of higher doses than the recommended geriatric doses. We asked responsible nurses to indicate the main problem for which the patient was using antipsychotics. They indicated antipsychotic use for restlessness and agitation in 63%, aggression in 11%, delusion and hallucinations in 11%, depression in 10% and anxiety in 5%.
Completion
All study participants completed at least the consecutive five days follow-up period after the abrupt discontinuation. The follow-up NPI scores after one month could only be obtained for 37 patients, since three patients had dropped out due to unrelated death (cancer and pneumonia; n ¼ 2) or adverse event (i.e. fall 14 days after discontinuation; n ¼ 1). During the consecutive five days follow-up, two study participants relapsed to antipsychotic use due to recurring delusions, hallucinations and/or agitation/aggression. At one month follow-up, four more participants had relapsed to antipsychotics of which two cases were restarted during hospitalisation, and two cases restarted after discharge at the nursing home. In three of these cases, patients suffered from delusions, hallucinations and/or agitation/aggression. Survival analysis investigated the time to relapse and revealed that the success rate over time was 95% after five days and 85% after 30 days (Figure 2) . Mean calculated survival time was 25 days.
Baseline NPI Baseline NPI scores indicated that the majority of problems were behavioural symptoms rather than psychological symptoms. Night-time behaviour problems in addition to agitation/aggression were the predominant disturbances. The study population had a mean total NPI score of 21 (SD 12; Table 2 ). When differentiating in baseline symptom NPI scores between the successfully discontinued and relapse group, we found higher baseline scores for the majority of NPI domains in the relapse group, but only statistically significant for the domain of night-time behaviour problems and for hallucinations. Also, when comparing the overall mean NPI between successful and relapse group, there was a significant higher score for the relapse group (p ¼ 0.007; Table 2 ).
Withdrawal symptoms
All study participants completed the consecutive five days follow-up with monitoring thrice a day of withdrawal symptoms by using a checklist. Mild withdrawal symptoms were observed in 72% of patients, peaking on the day 2 (53%) and day 3 (48%) and more often occurring at night. Psychological symptoms were reported in 67% of patients while physical symptoms occurred in 15% (Table 3 and Figure 3 ). Included physical deterioration, as well as a condition of neglect and/or pending for institutionalisation; b defined as acute and severe confusion and/or cognitive diagnostics; and c Length of study follow-up was 30 days, but the long mean length of stay was mainly due to patients from the psychogeriatric clinic who were already long-term hospitalised before the start of the study.
Changes in NPI scores one month after antipsychotic discontinuation
Study participants with successful antipsychotic discontinuation after one month had significantly improved (p ¼ 0.003) on the total mean NPI score, decreasing from 18.1 (SD 12.6) to 12.4 (SD 7.9). They had lower mean NPI scores on 11 out of 12 NPI domains, but most of these improvements were not statistically significant, except for the item hallucinations (p ¼ 0.017). A small decrease in total mean NPI of the relapse group while back on antipsychotics was from 30.7 (SD 7.3) to 27.2 (SD 11.8) (p ¼ 0.345). There was a nonsignificant trend to improvement on six out of 12 domains, especially for irritability, delusions, hallucinations and anxiety. In this group, we found nonsignificant increasing domain scores for agitation/ aggression, apathy and disinhibition. In the successful group, there were benefits for the cluster mood as well as for the cluster psychosis with lower mean scores compared to baseline. In the relapse group, there was no deterioration associated with the abrupt discontinuation and subsequent resumption of therapy with possible benefits for the cluster restlessness, agitation and psychosis. For the cluster mood there was no change (Table 2) .
Discussion
To our knowledge, this study is the first to investigate the effects of abrupt antipsychotic discontinuation in cognitively impaired, geriatric inpatients with attention to withdrawal phenomena and neuropsychiatric symptom changes over time. Mild withdrawal symptoms were common after abrupt discontinuation, but these symptoms weaned quickly over time, and led to relapse of antipsychotics in only a small minority of patients (n ¼ 2). At one-month follow-up, 85% of participants were still off antipsychotics. We anticipated that patients discharged from the hospital to the nursing home would rapidly resume antipsychotic treatment, but this was not the case at one month follow-up.
Patients who relapsed to antipsychotics had more severe baseline symptoms, and needed resumption of therapy. Our study confirmed that high baseline antipsychotic doses and severe baseline behavioural scores are predictive for relapse and deteriorating behavioural effects after discontinuation (Ruths et al., 2008; van Reekum et al., 2002) . However, patients relapsing to antipsychotics showed no residual effects or deteriorating behaviour as a result of a period of discontinuation and subsequent resumption of therapy, still leading to a trend of some modest improved NPI domains. Patients who were successfully discontinued shared a clinically relevant and statistically significant improvement on the total mean NPI score and some of the subscores. Also other studies have confirmed our finding that the course of behavioural symptoms improves or remains stable after antipsychotic discontinuation (Kleijer et al., 2009; Ruths et al., 2008) . Our study findings suggest that behavioural disturbances in dementia are fluctuating and cognitively impaired older persons often do not benefit from long-term antipsychotic treatment. Systematically performed discontinuation efforts in clinical practice are needed to differentiate between patients where antipsychotics have no added value, and patients where the benefits outweigh the risks. Gradual tapering is often recommended because of potential withdrawal symptoms, and is the result from studies with schizophrenic patients (Chouinard & Jones, 1980; Gardos et al., 1978; Viguera, Baldessarini, Hegarty, van Kammen, & Tohen, 1997) using higher doses of antipsychotics than older persons for the indication of BPSD. Furthermore, there is little information about the effects of gradual versus abrupt antipsychotic discontinuation in older persons with dementia, and the relationship with dosages, nor a standardised discontinuation schedule. We found that abrupt discontinuation of antipsychotics is feasible in older persons who are mostly using antipsychotics chronically in low, stable doses for their BPSD. However, monitoring of withdrawal symptoms is always necessary and caution is still required in patients using high antipsychotic doses.
Limitations
We performed an observational uncontrolled pilot study in which we assessed the feasibility and the effects of abrupt antipsychotic discontinuation, as a part of usual care in a 'real world' setting. Despite the inclusion of three institutions, we still had a small sample, mainly due to some resistance at the start of the study with consequences on the ease of recruitment. The inherent limitation of a pilot study is often the small sample, and the consecutive lack of sufficient power to make strong statements based on the results. Also, subgroup analyses (e.g. type of dementia) were not possible due to our small sample. Nevertheless, in our opinion, a pilot study exploring abrupt antipsychotic discontinuation was necessary before performing a large intervention study. A potential selection bias cannot be excluded for potentially eligible patients in which doctors did not perform discontinuation. Our study included cognitively impaired long-term users in which antipsychotic discontinuation should be considered according to best practice in a 'real world' setting, excluding patients with psychiatric comorbidities and acute behavioural problems in which continuation of antipsychotic treatment may be justified. Therefore, our study is, however, not representative in these patients. As the study progressed, perceptions and attitudes positively changed when clinical improvements were seen in patients. The clinical improvement mainly included the clearing up of the antipsychotic induced drowsiness and sedation. Unfortunately, we could not further explore the process of clearing up mainly because of a lack of standardised assessment tool to measure these rather 'clinical' effects in cognitively impaired older people. It is possible that part of the high success rate and NPI improvement in successfully discontinued patients could be the consequence of a higher tolerability of behavioural problems, more knowledge and altered perceptions, induced by the study. We performed a pilot study to detect whether abrupt discontinuation would be feasible, and deliberately have chosen a hospital setting in order to detect adverse effects associated with the abrupt discontinuation in due time. The detection of withdrawal symptoms was recorded by nurses and researchers based on a specifically developed but not validated checklist. There are few studies on antipsychotic withdrawal symptoms (Dilsaver & Alessi, 1988; Gardos et al., 1978) and there is no validated tool to observe them, in contrast to the field of benzodiazepine withdrawal (Couvee & Zitman, 2002) . We recorded a high prevalence of mild withdrawal symptoms mainly because our checklist was very sensitive and symptoms were recorded thrice a day (day, evening and night). However, the symptoms weaned quickly over time suggesting that the symptoms were in fact withdrawal symptoms associated with the abrupt discontinuation. Three patients dropped out, of which two participants died due to unrelated physical illness. Drop out due to death in older patients was expected since our population consists of frail older persons being hospitalised.
One participant had an adverse event (fall) two weeks after the discontinuation, which was retrospectively reported to the researchers. The relation between this adverse event and the antipsychotic discontinuation is unclear, knowing that older people have an increased risk of falling with several underlying factors, and that falls are frequent, also among non-antipsychotic users.
Implications for research
The results of this pilot study with regard to abrupt discontinuation suggest that abrupt discontinuation is feasible, and that larger confirmatory intervention studies controlling for type of dementia and potentially confounding factors in a hospital or nursing home setting with long-term follow-up are needed. Antipsychotic discontinuation in a hospital setting should also be further explored as an alternative to discontinuation programmes in the nursing home, unburdening nursing home staff from the decisionmaking and from monitoring after discontinuation. Discontinuation programmes in hospitals or nursing homes should always start with sufficient educational sessions for nurses and doctors to guarantee participation and involvement.
Implications for practice
Abrupt antipsychotic discontinuation in older individuals with BPSD appears to be feasible with a high success rate after one month. Discontinuation efforts are needed to identify patients in which continuing antipsychotics have no added value, and patients in which continuing treatment may be justified. Credible efforts should be undertaken to convince doctors and nursing staff in hospitals and nursing homes of the importance of antipsychotic discontinuation.
